Who is sponsoring HUM21469?

HUM21469 is sponsored by University of Michigan Rogel Cancer Center.

What condition does HUM21469 study?

HUM21469 studies Nausea, Vomiting, Terminally Ill.

What is the status of HUM21469?

HUM21469 is currently TERMINATED.

Last reviewed 2015-11-05 · How we verify

UMCC 2008.048 Palonosetron for the Treatment of Nausea and Vomiting in Terminally Ill Patients (HUM21469)

NCT00982995 Phase 2 TERMINATED Results posted

The primary objective of this study is to determine the complete response (no vomiting and no need for other medications to treat nausea) in terminally ill patients suffering from nausea and/or vomiting, who are treated with palonosetron. Another objective is to determine the partial response (relief of nausea and vomiting to the extent that the patient wishes to continue treatment with palonosetron) after being treated with palonosetron. Palonosetron is currently approved by the FDA to prevent nausea and vomiting associated with chemotherapy. The investigators are testing this medication to see if it can help to relieve nausea and vomiting not associated with chemotherapy.

Details

Lead sponsor	University of Michigan Rogel Cancer Center
Phase	Phase 2
Status	TERMINATED
Enrolment	3
Start date	2010-11
Completion	2013-05

Conditions

Nausea
Vomiting
Terminally Ill

Interventions

Palonosetron

Primary outcomes

To Determine the Complete Response (no Vomiting and no Need for Nausea Rescue Medication) in Terminally Ill Patients Suffering From Nausea and/or Vomiting, Treated With Palonosetron. — 96 hours after dosing

Countries

United States